Chemomab TherapeuticsSTU:2QV 34 Market Cap is €21.46 Mil as of Jul. 03, 2026. GuruFocus rates STU:2QV with a GF Score™ of 34/100. Among 1,426 Biotechnology companies, Chemomab Therapeutics ranks worse than 79.24% on this metric.
Chemomab Therapeutics's quarterly market cap
increased
from Sep. 2025 (€18.34 Mil) to Dec. 2025 (€21.43 Mil) and
increased
from Dec. 2025 (€21.43 Mil) to Mar. 2026 (€21.46 Mil).
Chemomab Therapeutics's annual market cap
increased
from Dec. 2023 (€6.51 Mil) to Dec. 2024 (€35.83 Mil) but then
declined
from Dec. 2024 (€35.83 Mil) to Dec. 2025 (€21.43 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Chemomab Therapeutics's Enterprise Value for Today is €14.43 Mil.
Chemomab Therapeutics (STU:2QV) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Chemomab Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemomab Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Chemomab Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Chemomab Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemomab Therapeutics (STU:2QV) has a Market Cap of €21.46 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Chemomab Therapeutics and its competitors. According to the industry distribution chart, Chemomab Therapeutics ranks #1130 out of 1426 companies in the Biotechnology industry, placing it in the top 79.2%.
Is Chemomab Therapeutics' Market Cap too high?
Chemomab Therapeutics' current Market Cap is €21.46 Mil. Based on the distribution chart, Chemomab Therapeutics ranks #1130 out of 1426 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chemomab Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Chemomab Therapeutics' Market Cap compare to OSRH and TOVX?
According to the Biotechnology industry distribution chart, Chemomab Therapeutics ranks #1130 out of 1426 companies for Market Cap. This places Chemomab Therapeutics in the lower half of its industry. The industry median Market Cap is 119.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Chemomab Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemomab Therapeutics's current Market Cap is €21.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemomab Therapeutics stock overvalued right now?
Chemomab Therapeutics (STU:2QV) has a current Market Cap of €21.46 Mil. The current Market Cap is €21.46 Mil. Chemomab Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Chemomab Therapeutics (STU:2QV), the current Market Cap is €21.46 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
34GF Score
Get the complete analysis for STU:2QV
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2QV has been successfully added to your 
